908 related articles for article (PubMed ID: 34503349)
1. Doxycycline Combined With Bortezomib-Cyclophosphamide-Dexamethasone Chemotherapy for Newly Diagnosed Cardiac Light-Chain Amyloidosis: A Multicenter Randomized Controlled Trial.
Shen KN; Fu WJ; Wu Y; Dong YJ; Huang ZX; Wei YQ; Li CR; Sun CY; Chen Y; Miao HL; Zhang YL; Cao XX; Zhou DB; Li J
Circulation; 2022 Jan; 145(1):8-17. PubMed ID: 34503349
[TBL] [Abstract][Full Text] [Related]
2. Cyclophosphamide-bortezomib-dexamethasone compared with bortezomib-dexamethasone in transplantation-eligible patients with newly diagnosed multiple myeloma.
Figueiredo A; Atkins H; Mallick R; Kekre N; Kew A; McCurdy A
Curr Oncol; 2020 Apr; 27(2):e81-e85. PubMed ID: 32489256
[TBL] [Abstract][Full Text] [Related]
3. Addition of cyclophosphamide and higher doses of dexamethasone do not improve outcomes of patients with AL amyloidosis treated with bortezomib.
Kastritis E; Gavriatopoulou M; Roussou M; Fotiou D; Ziogas DC; Migkou M; Eleutherakis-Papaiakovou E; Panagiotidis I; Kanellias N; Psimenou E; Papadopoulou E; Pamboucas C; Manios E; Gakiopoulou H; Ntalianis A; Tasidou A; Giannouli S; Terpos E; Dimopoulos MA
Blood Cancer J; 2017 Jun; 7(6):e570. PubMed ID: 28622303
[TBL] [Abstract][Full Text] [Related]
4. Daratumumab: A Review in Newly Diagnosed Systemic Light Chain Amyloidosis.
Blair HA
Drugs; 2022 Apr; 82(6):683-690. PubMed ID: 35416593
[TBL] [Abstract][Full Text] [Related]
5. Cyclophosphamide, Bortezomib and Dexamethasone (CyBorD) for the Treatment of Newly Diagnosed AL Amyloidosis: Impact of Response on Survival Outcomes.
Diaz-Pallares C; Lee H; Luider J; Duggan P; Neri P; Tay J; MacCulloch S; Bahlis NJ; Jimenez-Zepeda VH
Clin Lymphoma Myeloma Leuk; 2020 Jun; 20(6):394-399. PubMed ID: 32146104
[TBL] [Abstract][Full Text] [Related]
6. A comparative study of cyclophosphamide, thalidomide and dexamethasone (CTD) versus bortezomib and dexamethasone (BDex) in light-chain amyloidosis.
Liu B; Wang Y; Ning X; Bai M; Wang D; Zhao J; Zhou M; Sun S
Curr Probl Cancer; 2021 Apr; 45(2):100669. PubMed ID: 33127168
[TBL] [Abstract][Full Text] [Related]
7. Cyclophosphamide-bortezomib-dexamethasone (CyBorD) produces rapid and complete hematologic response in patients with AL amyloidosis.
Mikhael JR; Schuster SR; Jimenez-Zepeda VH; Bello N; Spong J; Reeder CB; Stewart AK; Bergsagel PL; Fonseca R
Blood; 2012 May; 119(19):4391-4. PubMed ID: 22331188
[TBL] [Abstract][Full Text] [Related]
8. Daratumumab plus CyBorD for patients with newly diagnosed AL amyloidosis: safety run-in results of ANDROMEDA.
Palladini G; Kastritis E; Maurer MS; Zonder J; Minnema MC; Wechalekar AD; Jaccard A; Lee HC; Bumma N; Kaufman JL; Medvedova E; Kovacsovics T; Rosenzweig M; Sanchorawala V; Qin X; Vasey SY; Weiss BM; Vermeulen J; Merlini G; Comenzo RL
Blood; 2020 Jul; 136(1):71-80. PubMed ID: 32244252
[TBL] [Abstract][Full Text] [Related]
9. Combined use of bortezomib, cyclophosphamide, and dexamethasone induces favorable hematological and organ responses in Japanese patients with amyloid light-chain amyloidosis: a single-institution retrospective study.
Kikukawa Y; Yuki H; Hirata S; Ide K; Nakata H; Miyakawa T; Matsuno N; Nosaka K; Yonemura Y; Kawaguchi T; Hata H; Mitsuya H; Okuno Y
Int J Hematol; 2015 Feb; 101(2):133-9. PubMed ID: 25430082
[TBL] [Abstract][Full Text] [Related]
10. Outcomes by Cardiac Stage in Patients With Newly Diagnosed AL Amyloidosis: Phase 3 ANDROMEDA Trial.
Minnema MC; Dispenzieri A; Merlini G; Comenzo RL; Kastritis E; Wechalekar AD; Grogan M; Witteles R; Ruberg FL; Maurer MS; Tran N; Qin X; Vasey SY; Weiss BM; Vermeulen J; Jaccard A
JACC CardioOncol; 2022 Nov; 4(4):474-487. PubMed ID: 36444227
[TBL] [Abstract][Full Text] [Related]
11. Sequential cyclophosphamide-bortezomib-dexamethasone unmasks the harmful cardiac effect of dexamethasone in primary light-chain cardiac amyloidosis.
Le Bras F; Molinier-Frenkel V; Guellich A; Dupuis J; Belhadj K; Guendouz S; Ayad K; Colombat M; Benhaiem N; Tissot CM; Hulin A; Jaccard A; Damy T
Eur J Cancer; 2017 May; 76():183-187. PubMed ID: 28334621
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of bortezomib, cyclophosphamide and dexamethasone in treatment-naïve patients with high-risk cardiac AL amyloidosis (Mayo Clinic stage III).
Jaccard A; Comenzo RL; Hari P; Hawkins PN; Roussel M; Morel P; Macro M; Pellegrin JL; Lazaro E; Mohty D; Mercie P; Decaux O; Gillmore J; Lavergne D; Bridoux F; Wechalekar AD; Venner CP
Haematologica; 2014 Sep; 99(9):1479-85. PubMed ID: 24859879
[TBL] [Abstract][Full Text] [Related]
13. Bortezomib with or without dexamethasone in primary systemic (light chain) amyloidosis.
Kastritis E; Wechalekar AD; Dimopoulos MA; Merlini G; Hawkins PN; Perfetti V; Gillmore JD; Palladini G
J Clin Oncol; 2010 Feb; 28(6):1031-7. PubMed ID: 20085941
[TBL] [Abstract][Full Text] [Related]
14. Daratumumab-Based Treatment for Immunoglobulin Light-Chain Amyloidosis.
Kastritis E; Palladini G; Minnema MC; Wechalekar AD; Jaccard A; Lee HC; Sanchorawala V; Gibbs S; Mollee P; Venner CP; Lu J; Schönland S; Gatt ME; Suzuki K; Kim K; Cibeira MT; Beksac M; Libby E; Valent J; Hungria V; Wong SW; Rosenzweig M; Bumma N; Huart A; Dimopoulos MA; Bhutani D; Waxman AJ; Goodman SA; Zonder JA; Lam S; Song K; Hansen T; Manier S; Roeloffzen W; Jamroziak K; Kwok F; Shimazaki C; Kim JS; Crusoe E; Ahmadi T; Tran N; Qin X; Vasey SY; Tromp B; Schecter JM; Weiss BM; Zhuang SH; Vermeulen J; Merlini G; Comenzo RL;
N Engl J Med; 2021 Jul; 385(1):46-58. PubMed ID: 34192431
[TBL] [Abstract][Full Text] [Related]
15. Real world outcomes with Bortezomib Thalidomide dexamethasone and Cyclophosphamide Bortezomib dexamethasone induction treatment for transplant eligible multiple myeloma patients in a Latin American country. A Retrospective Cohort Study from Grupo Argentino de Mieloma Múltiple.
Schütz NP; Ochoa P; Duarte P; Remaggi G; Yantorno S; Corzo A; Zabaljauregui S; Shanley C; Lopresti S; Orlando S; Verri V; Quiroga L; García CA; Fernández V; Fantl D
Hematol Oncol; 2020 Aug; 38(3):363-371. PubMed ID: 32196120
[TBL] [Abstract][Full Text] [Related]
16. A European collaborative study of cyclophosphamide, bortezomib, and dexamethasone in upfront treatment of systemic AL amyloidosis.
Palladini G; Sachchithanantham S; Milani P; Gillmore J; Foli A; Lachmann H; Basset M; Hawkins P; Merlini G; Wechalekar AD
Blood; 2015 Jul; 126(5):612-5. PubMed ID: 25987656
[TBL] [Abstract][Full Text] [Related]
17. Translocation t(11;14) is associated with adverse outcome in patients with newly diagnosed AL amyloidosis when treated with bortezomib-based regimens.
Bochtler T; Hegenbart U; Kunz C; Granzow M; Benner A; Seckinger A; Kimmich C; Goldschmidt H; Ho AD; Hose D; Jauch A; Schönland SO
J Clin Oncol; 2015 Apr; 33(12):1371-8. PubMed ID: 25779559
[TBL] [Abstract][Full Text] [Related]
18. Bortezomib with dexamethasone as first-line treatment for AL amyloidosis with renal involvement.
Huang X; Wang Q; Chen W; Ren G; Liu Z
Amyloid; 2016; 23(1):51-7. PubMed ID: 26862817
[TBL] [Abstract][Full Text] [Related]
19. Daratumumab in first-line treatment of patients with light chain amyloidosis and Mayo stage IIIb improves treatment response and overall survival.
Oubari S; Hegenbart U; Schoder R; Steinhardt M; Papathanasiou M; Rassaf T; Thimm A; Hagenacker T; Naser E; Duhrsen U; Reinhardt HC; Kortum M; Agis H; Schonland S; Carpinteiro A
Haematologica; 2024 Jan; 109(1):220-230. PubMed ID: 37439344
[TBL] [Abstract][Full Text] [Related]
20. Efficacy of Chemotherapy for Light-Chain Amyloidosis in Patients Presenting With Symptomatic Heart Failure.
Sperry BW; Ikram A; Hachamovitch R; Valent J; Vranian MN; Phelan D; Hanna M
J Am Coll Cardiol; 2016 Jun; 67(25):2941-8. PubMed ID: 27339491
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
